Cordarone
Cordarone
- Cordarone (amiodarone) is a prescription-only medicine in the UK and most countries and should normally be dispensed by pharmacies only with a valid prescription; branded and generic forms are available from community and hospital pharmacies and authorised suppliers.
- Cordarone is used to treat serious ventricular arrhythmias (ventricular tachycardia, refractory ventricular fibrillation) and sometimes atrial fibrillation; it is mainly a Class III antiarrhythmic that prolongs cardiac action potentials and refractory periods, with additional class I, II and IV effects.
- Usual dosage: oral loading 800–1600 mg/day in divided doses until initial response (typically 1–3 weeks), then reduction to 600–800 mg/day for about a month, and maintenance commonly 200–400 mg/day personalised to the patient; intravenous regimens are used in hospital (eg. 150 mg over 10 minutes then infusion at 1 mg/min for 6 hours then 0.5 mg/min).
- Form of administration: oral scored tablets (100 mg and 200 mg) for outpatient use and intravenous solution/vials (eg. 50 mg/mL) for inpatient/emergency use.
- Onset time: when given intravenously effects can begin within minutes to hours (initial bolus over 10 minutes), whereas oral therapy usually requires days to weeks for full effect, often 1–3 weeks during loading.
- Duration of action: very long due to tissue accumulation — clinical effects and drug levels may persist for weeks to months after stopping (typical elimination half‑life is prolonged, often measured in many weeks).
- Alcohol warning: avoid excessive alcohol while taking amiodarone because alcohol can increase the risk of liver injury and may worsen side effects; discuss alcohol intake with your prescriber and have liver function monitored as advised.
- The most common side effect is thyroid dysfunction (hypothyroidism or hyperthyroidism); other frequent adverse effects include nausea, photosensitivity and skin discolouration, corneal microdeposits, tremor and potential pulmonary toxicity.
- Would you like to try cordarone without a prescription?
Latest Research Highlights (UK & EU, 2022–2025)
Basic Cordarone Information
- INN (International Nonproprietary Name): Amiodarone (Latin: Amiodaronum).
- Brand Names Available In United Kingdom: Cordarone X; generic Amiodarone (available in 28/30/100 tablet packs).
- ATC Code: C01BD01 — cardiovascular, cardiac therapy, antiarrhythmics class III; amiodarone also shows class I, II and IV effects.
- Forms & Dosages: Scored tablets 100 mg and 200 mg; parenteral solution/vials 50 mg/mL for IV use.
- Manufacturers In United Kingdom: Sanofi (Cordarone brand) and multiple generics from manufacturers such as Sandoz, Teva and Orion.
- Registration Status In United Kingdom: Approved by MHRA; prescription-only medicine.
- OTC / Rx Classification: Rx only — not available over the counter in routine practice.
Worried about the latest evidence on cordarone and how it affects treatment choices?
Recent UK and EU observational registries and multicentre cohorts from 2022–2025 have reinforced a familiar clinical trade-off for amiodarone: potent suppression of dangerous ventricular arrhythmias at the price of cumulative extracardiac toxicity.
Large NHS trust registries report sustained efficacy in ventricular tachycardia and ventricular fibrillation and improved rhythm control in patients who have failed other agents.
Meta-analyses and systematic reviews from the period note limited randomised trial evidence for long-term mortality benefit and considerable heterogeneity between studies.
Safety surveillance through MHRA Yellow Card reports and EMA periodic safety updates continues to flag thyroid dysfunction and interstitial lung disease as major concerns with clinical consequence.
In UK practice, cardiology teams favour amiodarone for acute or refractory ventricular arrhythmias while applying stringent monitoring protocols and documented shared decision-making.
Clinicians typically follow baseline liver function tests, thyroid function tests and chest imaging prior to long-term use.
| Study Type | Main Outcome | Clinical Takeaway |
|---|---|---|
| Large NHS Observational Registries | Sustained arrhythmia suppression | Useful for refractory VT/VF; monitoring essential |
| Multicentre EU Cohorts | Symptom and ICD shock reduction | Efficacy in complex cases; adverse events higher vs newer agents |
| Systematic Reviews/Meta-analyses | Heterogeneous results for mortality | Long-term mortality benefit unclear |
Data Highlight: thyroid dysfunction and interstitial lung disease remain the most reported serious harms in UK/EU pharmacovigilance systems.
Clinical Effectiveness In The UK (NHS Outcomes & Patient-Reported)
Are patients seeing real benefit from cordarone in NHS settings?
NHS audits and hospital outcome reports show that amiodarone reliably converts or suppresses life-threatening ventricular arrhythmias when alternatives have failed.
Cardiology outpatient follow-up data and registries often document fewer ICD shocks and symptomatic improvement in patients stabilised on maintenance therapy.
Patient-reported outcomes commonly record improved quality of life when rhythm control is achieved, alongside frequent concerns about side effects such as fatigue and tremor.
Typical UK practice uses IV amiodarone for inpatient loading and oral maintenance dosing of 200–400 mg/day, tailored to response and tolerability.
Economic analyses within NHS pathways tend to accept higher monitoring costs because emergency admissions and ICD therapies are reduced.
| Source | NHS Audit / Registry Finding | Patient-Reported Item |
|---|---|---|
| Hospital Audit | Reduced ICD shocks; fewer arrhythmia readmissions | Relief from palpitations; improved sleep |
| Cardiology Registry | High efficacy in refractory VT/VF | Worry over long-term side effects |
Common Patient-Reported Symptoms:
- Fatigue and dizziness.
- Tremor and sleep disturbance.
- Photosensitivity and skin changes.
Service design in the NHS works best when cardiology, pharmacy and primary care share monitoring responsibilities and test results are available on patient portals.
Indications & Expanded Uses (MHRA-Approved And Off-Label NHS Practice)
When will a clinician choose cordarone over other drugs?
MHRA-approved indications in the UK align with major regulators and include refractory ventricular fibrillation and ventricular tachycardia, with IV formulations reserved for acute management and oral tablets for maintenance.
Off-label NHS uses commonly include atrial fibrillation in patients intolerant of or refractory to other agents, and complex supraventricular arrhythmias managed by electrophysiology teams.
Amiodarone’s pharmacology includes predominant class III antiarrhythmic action with additional class I, II and IV effects, which explains its broad rhythm effect and why it is reserved for higher-risk scenarios.
| MHRA-Approved Uses | Common Off-Label NHS Uses |
|---|---|
| Refractory Ventricular Fibrillation | Atrial Fibrillation When Other Agents Fail |
| Ventricular Tachycardia | Complex Supraventricular Arrhythmias |
Decision frameworks in NHS cardiology groups generally require a risk–benefit assessment, documented consent and multidisciplinary review for long-term therapy.
Composition & Brand Landscape (Active Ingredients; UK Brands)
Which Cordarone products are seen on UK shelves and in hospitals?
The active ingredient is amiodarone (INN: Amiodarone; ATC: C01BD01), a lipophilic benzofuran derivative that accumulates in tissues.
UK market products commonly include Cordarone X and generic amiodarone tablets; Cordarone IV is used in hospitals for parenteral administration.
| Brand | Formulation | Pack Sizes | Supplier / Manufacturer |
|---|---|---|---|
| Cordarone X | Tablets 100 mg, 200 mg | 28 / 30 / 100 | Sanofi (brand) |
| Generic Amiodarone | Tablets 100 mg, 200 mg | 28 / 30 / 100 | Sandoz, Teva, Orion (generics) |
| Cordarone IV | Parenteral 50 mg/mL vials | IV vials (hospital supply) | Hospital procurement |
Excipient Cautions:
- Check for excipient allergies on product labelling before supply.
- Inform patients about tablet scoring and the importance of not crushing sustained-release forms if present.
Contraindications & Special Precautions (High-Risk Groups)
Who must not take cordarone or needs special review before starting?
Absolute contraindications include known hypersensitivity to amiodarone or iodine, significant sinus node dysfunction, high-grade AV block without a pacemaker, untreated severe thyroid disease and pregnancy unless the arrhythmia is life-threatening.
Relative cautions apply to patients with pre-existing interstitial lung disease, hepatic impairment, untreated electrolyte disturbances and advanced age.
| Absolute Contraindication | Relative Contraindication / Caution |
|---|---|
| Hypersensitivity To Amiodarone Or Iodine | Interstitial Lung Disease |
| Severe Sinus Node Dysfunction | Liver Dysfunction — dose reduction and monitoring needed |
| High-Grade AV Block Without Pacemaker | Concurrent QT-Prolonging Medicines |
Practical NHS notes: pregnant women should have a multidisciplinary review before exposure and elderly patients generally start on lower doses with closer monitoring.
Advice routinely given to patients includes strict sun protection for photosensitivity and caution with alcohol because of hepatic risk.
Dosage Guidelines (NHS-Recommended Regimens & Adjustments)
How is cordarone started and maintained in NHS practice?
Oral adult loading doses commonly range from 800–1600 mg/day in divided doses until an initial response, usually over 1–3 weeks.
After initial control, clinicians commonly reduce to 600–800 mg/day for approximately one month before stepping down to maintenance, typically 200–400 mg/day tailored to effect and toxicity.
Hospital IV protocol often follows an initial 150 mg over 10 minutes, then 1 mg/min for 6 hours, then 0.5 mg/min for 18 hours in emergency settings.
Special populations require adjustment: start lower in elderly patients, reduce dose and intensify monitoring in hepatic impairment and use specialist weight-based dosing for paediatrics.
- Loading Phase: 800–1600 mg/day in divided doses (1–3 weeks).
- Reduction Phase: 600–800 mg/day for ~1 month.
- Maintenance Phase: 200–400 mg/day long term.
Practical tip: take doses consistently with meals for tolerability and ensure clear discharge instructions are recorded in the NHS summary care record.
Interactions Overview (Food, Drink, MHRA Yellow Card Reports)
What medicines or foods change how cordarone works or increase risks?
Amiodarone has clinically important interactions with warfarin (increased INR), digoxin (potentiation), statins (CYP interactions and rare rhabdomyolysis), and many QT-prolonging medicines.
P-glycoprotein and CYP enzyme interactions mean dose adjustments and monitoring are frequently needed for drugs such as certain statins and direct oral anticoagulants.
There are no strict food prohibitions, but counsel patients to moderate alcohol intake because of hepatic risk and advise that stimulants like excess caffeine can worsen palpitations symptomatically.
| Interacting Drug | Effect | Recommended Action |
|---|---|---|
| Warfarin | Increased INR | Reduce warfarin dose and increase INR monitoring |
| Digoxin | Increased digoxin levels | Reduce digoxin by ~25–50% and monitor clinically |
| Statins (certain) | Increased statin exposure, rare rhabdomyolysis | Use lower statin doses or choose safer alternatives; monitor for myopathy |
MHRA Yellow Card reports include interaction-related adverse events such as elevated INR and cases where combined therapy led to significant harms; pharmacists should report suspected interactions.
Pharmacy practice point: do a medicines reconciliation checklist on every dispensing and provide written interaction advice to patients.
Cultural Perceptions & Patient Habits (UK Forums, Trust In Pharmacists)
What do patients in the UK talk about when they look up cordarone online?
UK forums such as Patient.info and condition-specific support groups commonly show gratitude for symptom control together with worry about the long-term side effects of amiodarone.
Parents and carers often ask for clear safety information and a stepwise monitoring plan before accepting long-term therapy.
There is strong cultural reliance on pharmacist counselling and NHS 111 for triage, and many patients expect written monitoring schedules and access to test results through NHS patient portals.
Use of e-prescriptions and online pharmacies for repeat supplies is rising, but many patients still prefer face-to-face counselling at community pharmacy chains.
Common Patient Concerns:
- How often will bloods and chest imaging be needed?
- Will side effects resolve after stopping the drug?
- Can photosensitivity or skin discolouration be prevented?
Sample Pharmacist Counselling Checklist:
- Explain purpose, dosing phases, and key side effects to report.
- Confirm monitoring schedule and how results are shared via the NHS portal.
- Advise on sun protection and when to seek urgent review.
Availability & Pricing Patterns (Boots, LloydsPharmacy, NHS Prescription Costs)
How easy is it for a UK patient to get Cordarone and what will it cost?
Cordarone X and generics are widely available through major chains such as Boots and LloydsPharmacy, hospital pharmacies and accredited online pharmacies supplying repeat prescriptions via the NHS Electronic Prescription Service.
NHS prescription charges differ by nation: patients in England may pay per item unless exempt, while Scotland, Wales and Northern Ireland provide free NHS prescriptions — this affects out-of-pocket costs for repeat amiodarone.
Private purchase prices vary by pack size and brand, and generics typically lower the cost for the patient.
In our online pharmacy, cordarone is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.
| Channel | Typical Availability | Price Pattern |
|---|---|---|
| Boots / LloydsPharmacy | In-store and online repeat supply | Brand and generic pricing; prescription charge applies in England if not exempt |
| Hospital Pharmacy | IV vials and acute supplies | Provided via NHS; no direct patient charge in devolved nations |
| Online Pharmacies | Repeat supplies with EPS | Private buy varies by brand and pack size |
Search queries often include price comparisons such as "Cordarone 200mg price" or "cordarone online UK".
Comparable Medicines And NHS Prescribing Preferences
Which alternatives might an NHS clinician consider instead of cordarone?
Common alternatives include sotalol, dronedarone, flecainide and propafenone, chosen according to arrhythmia type and patient comorbidities.
Sotalol offers class III action with beta-blocking properties but carries torsades de pointes risk and typically needs in-hospital initiation.
Dronedarone has fewer extracardiac effects but is less effective for ventricular arrhythmias and is not a direct substitute where life-threatening ventricular arrhythmias are present.
| Comparator | Pros | Cons |
|---|---|---|
| Sotalol | Good for some supraventricular and ventricular arrhythmias | Requires monitoring for QT prolongation; hospital initiation often needed |
| Dronedarone | Lower extracardiac toxicity | Less effective for ventricular arrhythmias |
| Flecainide / Propafenone | Effective for paroxysmal AF without structural heart disease | Contraindicated with ischaemic heart disease or left ventricular dysfunction |
NHS formularies typically reserve amiodarone for refractory or high-risk cases because of its monitoring burden and extracardiac risks.
Frequently Asked Questions
What are the short answers patients ask most about cordarone in the NHS?
- How quickly does amiodarone work? IV loading can produce effects within minutes to hours in hospital. Oral loading usually takes days to weeks for full effect.
- What monitoring is needed? Baseline and periodic liver function tests, thyroid function tests, chest X-ray (or CT if respiratory symptoms), ECGs and eye checks when indicated.
- Can I stop if I get side effects? Do not stop abruptly; contact the GP or cardiology team because adverse effects may persist due to tissue accumulation.
- Is it safe in pregnancy? Generally avoided unless maternal life-threatening arrhythmia requires treatment; specialist multidisciplinary review is needed.
Downloadable Clinic Checklist: provide patients with a one-page checklist showing dates for blood tests, chest imaging and cardiology review.
Guidelines For Proper Use (Pharmacist Counselling & NHS Support)
What should pharmacists tell patients receiving cordarone?
Pharmacist counselling should cover the drug’s purpose, the difference between loading and maintenance phases, dosing schedules and the most important side effects to report, such as breathlessness, visual changes, jaundice or new thyroid symptoms.
Interaction checks should be emphasised, particularly with warfarin, digoxin and certain statins, and written action points should be given for when to seek urgent care.
Use NHS patient portals to upload monitoring results and set automated reminders for testing where available.
Community pharmacy workflow benefits from a medicines use review template and a clear contact algorithm for urgent symptoms.
- Ensure the patient’s summary care record reflects monitoring plans and recent blood tests.
- Signpost to cardiology clinic contact details and NHS resources for ongoing support.
Delivery Across United Kingdom
| City | Region | Delivery Time |
|---|---|---|
| London | England | 5-7 days |
| Birmingham | England | 5-7 days |
| Manchester | England | 5-7 days |
| Glasgow | Scotland | 5-7 days |
| Edinburgh | Scotland | 5-7 days |
| Bristol | England | 5-7 days |
| Leeds | England | 5-7 days |
| Belfast | Northern Ireland | 5-9 days |
| Cardiff | Wales | 5-9 days |
| Newcastle | England | 5-9 days |
| Southampton | England | 5-9 days |
| Norwich | England | 5-9 days |
| Plymouth | England | 5-9 days |
| Inverness | Scotland | 5-9 days |
Delivery times are estimates and depend on stock and courier schedules.
Closing Practical Notes For Patients And Clinicians
How to make cordarone safer for the patient in routine NHS care.
Before starting, check baseline LFTs, TFTs and obtain chest imaging when indicated and document informed consent when prescribing for long-term use.
Provide patients with a clear monitoring schedule and a written action plan that tells them what symptoms should prompt urgent contact with their GP or cardiology team.
Pharmacists should reconcile medicines at each dispensing, counsel on interactions and ensure monitoring is up to date in the summary care record.
Report suspected adverse drug reactions through the MHRA Yellow Card scheme.